BioRestorative Therapies (BRTX) Intangibles (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Intangibles came in at $534198.0 in Q4 2025, down 14.38% YoY from $623945.0 in Q4 2024, and down 4.03% on a QoQ basis from $556634.0 in Q3 2025.
BioRestorative Therapies (BRTX) Intangibles (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Intangibles data on file, last reported at $534198.0 in Q4 2025.
- Quarterly Intangibles fell 14.38% year-over-year to $534198.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $534198.0 (down 14.38% YoY) and the FY2025 annual result came in at $534198.0, down 14.38% from the prior year.
- Intangibles fell to $534198.0 in Q4 2025, from $556634.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $1.6 million in Q4 2022 to a low of $530298.0 in Q3 2022.
- A 5-year average of $759959.4 and a median of $636320.0 in 2021 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2021 — Intangibles surged 95.93% — and 2024, when it sank 60.85%.
- Tracing BRTX's Intangibles over 5 years: stood at $1.3 million in 2021, then climbed by 22.44% to $1.6 million in 2022, then changed by 0.0% to $1.6 million in 2023, then slumped by 60.85% to $623945.0 in 2024, then slipped by 14.38% to $534198.0 in 2025.
- The last three Intangibles figures came in at $534198.0 (Q4 2025), $556634.0 (Q3 2025), and $579071.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 | 534,198.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 534,198.00 |
| Sep 30, 2025 | 556,634.00 |
| Jun 30, 2025 | 579,071.00 |
| Mar 31, 2025 | 601,508.00 |
| Dec 31, 2024 | 623,945.00 |
| Sep 30, 2024 | 646,381.00 |
| Jun 30, 2024 | 668,818.00 |
| Mar 31, 2024 | 691,255.00 |
| Dec 31, 2023 | 1.59 Mn |
| Sep 30, 2023 | 736,128.00 |
| Jun 30, 2023 | 758,565.00 |
| Mar 31, 2023 | 781,002.00 |
| Dec 31, 2022 | 1.59 Mn |
| Sep 30, 2022 | 530,298.00 |
| Jun 30, 2022 | 550,703.00 |
| Mar 31, 2022 | 571,109.00 |
| Dec 31, 2021 | 1.30 Mn |
| Sep 30, 2021 | 608,372.00 |
| Jun 30, 2021 | 627,004.00 |
| Mar 31, 2021 | 645,636.00 |